Flexion Therapeutics (NASDAQ:FLXN) Stock Rating Lowered by BidaskClub

Flexion Therapeutics (NASDAQ:FLXN) was downgraded by BidaskClub from a “sell” rating to a “strong sell” rating in a note issued to investors on Saturday, January 20th.

FLXN has been the topic of a number of other research reports. Wells Fargo & Co set a $39.00 price objective on shares of Flexion Therapeutics and gave the stock a “buy” rating in a report on Monday, October 30th. Zacks Investment Research downgraded shares of Flexion Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, October 17th. Northland Securities restated a “buy” rating and set a $40.00 target price on shares of Flexion Therapeutics in a research report on Wednesday, October 4th. Needham & Company LLC upped their target price on shares of Flexion Therapeutics from $36.00 to $42.00 and gave the company a “buy” rating in a research report on Monday, October 9th. Finally, ValuEngine upgraded shares of Flexion Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, December 31st. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $99.11.

Shares of Flexion Therapeutics (NASDAQ:FLXN) traded up $0.72 during trading on Friday, reaching $24.41. 535,793 shares of the company’s stock traded hands, compared to its average volume of 715,310. The company has a debt-to-equity ratio of 0.87, a current ratio of 12.93 and a quick ratio of 12.93. Flexion Therapeutics has a 12-month low of $16.51 and a 12-month high of $32.25. The company has a market cap of $871.70, a price-to-earnings ratio of -6.95 and a beta of 0.91.

In other news, insider Neil Bodick bought 2,700 shares of the firm’s stock in a transaction that occurred on Tuesday, November 21st. The stock was acquired at an average cost of $24.49 per share, with a total value of $66,123.00. Following the completion of the purchase, the insider now owns 64,605 shares of the company’s stock, valued at $1,582,176.45. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 15.98% of the stock is currently owned by company insiders.

A number of hedge funds have recently bought and sold shares of FLXN. Wells Fargo & Company MN raised its stake in Flexion Therapeutics by 1,024.1% in the fourth quarter. Wells Fargo & Company MN now owns 1,706,942 shares of the specialty pharmaceutical company’s stock valued at $42,742,000 after purchasing an additional 1,555,093 shares in the last quarter. State Street Corp raised its stake in Flexion Therapeutics by 66.3% in the second quarter. State Street Corp now owns 1,379,202 shares of the specialty pharmaceutical company’s stock valued at $27,888,000 after purchasing an additional 549,948 shares in the last quarter. BlackRock Inc. raised its stake in Flexion Therapeutics by 17.4% in the fourth quarter. BlackRock Inc. now owns 2,650,986 shares of the specialty pharmaceutical company’s stock valued at $66,381,000 after purchasing an additional 392,055 shares in the last quarter. Wasatch Advisors Inc. grew its position in Flexion Therapeutics by 58.7% in the second quarter. Wasatch Advisors Inc. now owns 1,018,219 shares of the specialty pharmaceutical company’s stock valued at $20,588,000 after acquiring an additional 376,745 shares during the last quarter. Finally, Perceptive Advisors LLC bought a new position in Flexion Therapeutics in the fourth quarter valued at about $7,712,000. 72.18% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: This news story was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this news story on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2018/02/14/bidaskclub-lowers-flexion-therapeutics-flxn-to-strong-sell.html.

Flexion Therapeutics Company Profile

Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.

Analyst Recommendations for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply